Alterity Therapeutics Obtained Approval for PBT434 From EC For MSA’s Treatment In EU

  • Jan 14, 2020 AEDT
  • Team Kalkine

Alterity Therapeutics Limited (ASX: ATH) has been granted Orphan Drug designation for its lead molecule, PBT434 by the European Commission (EC) for the treatment of Multiple System Atrophy (MSA).

Orphan Drug designation by the EC allows the company to 10 years of market exclusivity in the European Union for the application of PBT434 for treating MSA and other benefits like support in developing clinical protocols, lowered fees & access to EU-funded research grants.

ATH was able to obtain approval based on the recommendation of a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products.




All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK